

## Cystic Fibrosis Committee meeting 6

**Date:** 04/11/2015

**NICE** National Institute for  
Health and Care Excellence

**Location:** Royal College of Obstetricians and Gynaecologists, London.

**Minutes:** Confirmed

<b>Committee members present:</b>		
Martin Walshaw (Chair)		(Present for notes 1 – 6)
Mandy Bryon (MB)		(Present for notes 1 – 6)
Alexander Darlington (AD)		(Present for notes 1 – 6)
Sarah Popple (SP)		(Present for notes 1 – 6)
Iolo Doull (ID)		(Present for notes 1 – 6)
Sarah Collins (SC)		(Present for notes 1 – 6)
Alexander Darlington (AD)		(Present for notes 1 – 6)
Helen McCabe (HM)		(Present for notes 1 – 6)
Zoe Elliot (ZE)		(Present for notes 1 – 6)
Helen Parrott (HeP)		(Present for notes 1 – 6)
Janis Bloomer (JB)		(Present for notes 1 – 6)
Keith Thompson (KT)		(Present for notes 1 – 6)
Elaine Edwards (EE)		(Present for notes 1 – 6)

<b>In attendance:</b>		
Stephen Murphy (SM)	Clinical Director	(Present for notes 1 – 6)
Vanessa Delgado Nunes (VDN)	Senior Research Fellow and Guideline Lead	(Present for notes 1 – 6)
Annabel Flint (AF)	Project Manager	(Present for notes 1 – 6)
Melanie Powell (MP)	Assistant Project Manager	(Present for notes 1 – 6)
Shona Burman-Roy (SBR)	Senior Research Fellow	(Present for notes 4 – 6)
Omnia Abdulrazeg (OA)	Research Fellow	(Present for notes 1 – 6)

Gemma Villanueva (GV)	Research Fellow	(Present for notes 1 – 6)
Zosia Beckles (ZB)	Information Scientist	(Present for notes 1 – 6)
Hugo Pedder (HP)	Statistician	(Present for notes 1 – 6)
Gemma Marceniuk (GM)	Health Economist	(Present for notes 1 – 6)

<b>Observers:</b>	
None.	

<b>Apologies:</b>	
Katie Perryman-Ford	Guidelines Commissioning Manager
Nichola MacDuff	Committee member

<b>1. Welcome and objectives for the meeting</b>				
<p>The Chair welcomed the Committee members and attendees to the sixth guideline committee meeting on Cystic Fibrosis. The Committee members and attendees introduced themselves.</p> <p>No members of the public asked to observe the meeting.</p> <p>The Chair informed the Committee that apologies had been received from NMD and KPF.</p> <p>The Chair outlined the objectives of the meeting, which included: the presentation of the evidence reviews for antimicrobial prophylaxis and immunomodulatory agents (non-NMA outcomes), the presentation of the draft health economics model for immunomodulatory agents and the drafting of protocols for cystic fibrosis related diabetes and exercise among those with cystic fibrosis.</p>				
<b>2. Declarations of interest</b>				
<p>The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was the diagnosis and management of Cystic Fibrosis.</p> <p>The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.</p>				
<b>Name</b>	<b>Job title,</b>	<b>Declarations of Interest, date</b>	<b>Type of</b>	<b>Decision taken</b>

	<b>organisation</b>	<b>declared</b>	<b>interest</b>	
Andrew Jones	Consultant and Honorary Reader in Respiratory Medicine and Cystic Fibrosis, North West Lung Centre, University Hospitals South Manchester NHS Foundation Trust	Vertex Pharmaceuticals have provided an unrestricted educational grant to his department to fund a one day Cystic Fibrosis meeting in 2016.	Non-personal financial specific	No further action necessary.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

### **3. Minutes of last meeting**

The Chair asked the Committee whether any changes were required to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

### **4. Presentations**

The Chair introduced GV, Research Fellow, and GM, Health economist, who gave a presentation on the evidence reviewed for the topic of antimicrobial prophylaxis. The Chair then led the committee through the process of drafting recommendations and LETRs for this topic.

The Chair introduced OA, Research Fellow, and GM, Health economist, who gave a presentation on the evidence reviewed for the topic of immunomodulatory agents (non-NMA outcomes). The Chair then led the committee through the process of drafting recommendations and LETRs for this topic.

GM then gave a presentation on the draft health economics model for the topic of immunomodulatory agents.

The Committee thanked everyone for their presentations and contribution to the development of the guideline.

### **5. Questions and discussion**

The committee discussed the draft protocol for the effectiveness of exercise programmes which was presented by Vanessa Delgado Nunes. The draft protocol was edited live on screen.

The committee discussed the draft protocol for monitoring cystic fibrosis related diabetes in patients with cystic fibrosis which was presented by SBR. The draft protocol was edited live on screen.

#### **6. Any other business**

There were no other items of business. MW thanked the Committee for attending and closed the meeting.

**Date of next meeting:** 13/01/16

**Location of next meeting:** Royal College of Obstetricians and Gynaecologists,  
London.